Robert Hopfner

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.

Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA.

Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

Rallybio Holdings LLC engages in the provision of healthcare services. The company is headquartered in New Haven, CT.

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA.

Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA.

Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL.